View Author
receptor som 230 sst 2 somatostatin patient effect level subtype expression release sst 5 treatment adenomas secretion analog binding octreotide hormone endocrinol srif-analog sst 5 receptors study insulin inhibition adenoma acth release gh release culture corticotroph acromegalic patients concentration control tumor affinity response sst subtypes growth metab acromegaly novel chapter disease growth hormone corticotroph adenomas endocrinology cushing -20 cells acromegalic somatostatin receptor subtypes glucose adenoma cells fsk-induced camp response gh-secreting value hek 293 cells regulation lambert agonist sst 5 mrna crh-induced acth release suppression tissue tumours glucocorticoid sst 1 gh secretion figure -14 van koetsveld pm -20 therapy bim -23a efficacy somatostatin receptors binding affinity compound ic 50 values igf-i experiment mouse
9 Most Recent Publications
|
A Case Series of Proton Pump Inhibitor-Induced Hypomagnesemia
(Article)
Hoorn, E.J. Hoek, J. van der Man, R.A. de Kuipers, E.J. Bolwerk, C.L. Zietse, R. |
2010-07-01
|
|
The somatostatin receptor subtype 5 in neuroendocrine tumours
(Article)
Hoek, J. van der Lamberts, S.W.J. Hofland, L.J. |
2010-03-01
|
|
Severe hyponatremia with high urine sodium and osmolality
(Article)
Hoek, J. van der Hoorn, E.J. Jong, G.M.T. de Janssens, E.N.W. Herder, W.W. de |
2009-11-01
|
|
Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas
(Article)
Hoek, J. van der Lamberts, S.W.J. Hofland, L.J. |
2007-04-01
|
|
The functional role of somatostatin receptor subtypes in pituitary adenomas
(Doctoral Thesis)
Hoek, J. van der |
2006-05-17
|
|
Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells.
(Article)
Hoek, J. van der Waaijers, M. Culler, M.D. Lamberts, S.W.J. Hofland, L.J. Koetsveld, P.M. van Sprij-Mooij, D. Feelders, R.A. Schmid, H.A. Schoeffter, P. Hoyer, D. Cervia, D. Taylor, J.E. |
2005-08-01
|
|
The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.
(Article)
Hofland, L.J. Hoek, J. van der Beckers, A. Lamberts, S.W.J. Feelders, R.A. Aken, M.O. van Koetsveld, P.M. van Waaijers, M. Sprij-Mooij, D. Bruns, C. Weckbecker, G. Herder, W.W. de |
2005-04-01
|
|
A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients
(Article)
Hoek, J. van der Poon, K.W. Uitterlinden, P. Boerlin, V. Bruns, C. Lewis, I. Lamberts, S.W.J. Weckbecker, G. Hofland, L.J. Krahnke, T. Herder, W.W. de Feelders, R.A. Lely, A.J. van der |
2004-01-01
|
|
The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro
(Article)
Hofland, L.J. Lely, A.J. van der Weckbecker, G. Feelders, R.A. Lamberts, S.W.J. Beckers, A. Hoek, J. van der Koetsveld, P.M. van Herder, W.W. de Waaijers, M. Sprij-Mooij, D. Bruns, C. |
2004-01-01
|
